Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06889649

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the immunotherapy Toripalimab in patients with recurrent metastatic renal cell carcinoma (RCC). Patients will receive a treatment regimen consisting of Axitinib, Toripalimab, and comprehensive multi-lesion SABR. The primary endpoint is Progression-Free Survival 1 (PFS1), and secondary endpoints include Progression-Free Survival 2 (PFS2), Overall Survival (OS), Local Control (LC), Objective Response Rate (ORR), and Disease Control Rate (DCR). Adverse events will be monitored according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0). The aim of this study is to explore a potentially more effective treatment combination for recurrent metastatic RCC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Radiation Therapy Immunotherapy Renal Cancer Metastatic Targeted Therapy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Location status: Recruiting

Location contact

Mingwei Ma

CONTACT

[email protected]

+86-15810160120

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathologically confirmed renal cell carcinoma with recurrent metastatic lesions confirmed by PET/CT or other systemic imaging.
  • Patients with ≤5 metastatic lesions amenable to complete lesion coverage radiotherapy; or >5 lesions with at least 3 suitable for radiotherapy as evaluated by the radiotherapy and imaging departments.
  • Age between 18-80 years.
  • Expected survival of ≥12 weeks.
  • Measurable disease based on RECIST Version 1.1.
  • ECOG performance status of 0-2.

Exclusion criteria

  • History of anti-PD-1 or PD-L1 antibody therapy, or radiotherapy.
  • Use of corticosteroids or other immunosuppressants within 14 days before treatment.
  • Autoimmune diseases.
  • History of other malignancies.
  • History of surgery within 28 days before treatment.
  • Allergy to study drug components.

Treatment and study plan

Stereotactic Ablative Body Radiotherapy (SABR)

Radiation

Radiation dose of 6-10 Gy per fraction, administered in 5 fractions for peripheral lesions. For lesions near organs at risk, partial-SABR will be used. If neither SABR nor partial-SABR is feasible, moderate hypofractionated radiotherapy (MHFRT) with curative doses will be applied.

TORIPALIMAB INJECTION(JS001 )

Drug

Toripalimab (intravenous infusion):

Dosage: 240 mg intravenously every 3 weeks. Frequency: Administered every 3 weeks for the duration of the study, until progression or unacceptable toxicity occurs or reach 2 years.

Axitinib (VEGF-TKI)

Drug

Axitinib (oral, tablet):

Dosage: 5 mg orally twice daily. Frequency: Daily, for the duration of the study, with continuation during progression or until intolerable side effects occur.

Primary outcomes

  1. Progression-Free Survival 1 (PFS1)

    Time frame: From the start of SABR treatment to the first disease progression, up to 2 years. This primary endpoint assesses how long patients survive without disease progression while receiving the combination therapy.

    PFS1 is defined as the time from the initiation of stereotactic ablative body radiotherapy (SABR) to the first occurrence of disease progression, as determined by radiological imaging (CT, MRI, or PET/CT) based on RECIST criteria. Disease progression is defined as an increase in the size of target lesions or the appearance of new lesions.

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From the start of treatment to death or until the end of the study (up to 3 years). This secondary endpoint will help evaluate the overall survival benefits of the combined treatment over a longer period.

    Overall survival is defined as the time from the start of treatment (SABR combined with Axitinib and Toripalimab) to death from any cause.

  2. Progression-Free Survival 2 (PFS2)

    Time frame: From the start of SABR treatment to the initiation of next-line treatment or death (an average of 3 year)

    PFS2 is defined as the time from the start of stereotactic ablative body radiotherapy (SABR) to the need for second-line treatment due to disease progression or clinical deterioration, or to death. This will be measured by assessing the time until the initiation of a next-line treatment regimen or the occurrence of death.

Other outcomes

  1. Local Control (LC)

    Time frame: Through study completion, an average of 3 year

    Local Control is defined as the percentage of patients who have no evidence of disease progression in the irradiated lesions after treatment

  2. Objective Response Rate (ORR)

    Time frame: From the start of treatment to the first radiological evaluation to the best response(an average of 6 months)

    Objective Response Rate is defined as the percentage of patients who achieve a complete response (CR) or partial response (PR)

  3. Disease Control Rate (DCR)

    Time frame: From the start of treatment to the first disease progression, up to 2 years.

    Disease Control Rate is defined as the percentage of patients who achieve a complete response (CR), partial response (PR), or stable disease (SD)

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

Prospective Study on the Efficacy and Safety of Stereotactic Ablative Body Radiotherapy Combined with Axitinib and Toripalimab in Recurrent or Metastatic Renal Cell Carcinoma

Important dates

Study start
2019
Primary completion
2027
Study completion
2028
First posted
Mar 21, 2025
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.